Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) (AttackMS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05418010 |
|
Recruitment Status :
Recruiting
First Posted : June 14, 2022
Last Update Posted : May 22, 2023
|
Sponsor:
Queen Mary University of London
Collaborators:
Biogen
UCL Queen Square Institute of Neurology
Moorfields Eye Hospital NHS Foundation Trust
Barts & The London NHS Trust
Information provided by (Responsible Party):
Queen Mary University of London
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | May 31, 2024 |
| Estimated Study Completion Date : | May 31, 2024 |